These studies, performed in either pharmaceutical companies or in contract research organizations, are routine in character. If, for example, hundreds of Ames assays a year are analyzed in a laboratory, using very different substances with different mechanisms in the same assay, this is done due to the need for cost minimization. Therefore, statistical approaches should be as robust as possible against real data configurations, as simple as possible for physicians to interpret, as clear as possible in relation to the false positive/ false negative rate, and available as validated software. One dilemma is that the bandwidth of approaches for design and analysis of toxicological studies is too broad from the above viewpoint. Moreover, some of the International Conference on Harmonisation (ICH) documents and national guidelines on toxicological issues include facts relevant to statistics. Unfortunately, these seem to be largely written by nonstatisticians. Therefore, there is a need for recommendations on statistical analysis. Two such papers were developed in preparation for the DIA meetings in Brugge (March 1996) and Tokyo (August 1996): one on mutagenicity studies (9) , the other on repeated toxicity studies (10) . A third paper, on animal carcinogenicity studies, is still under preparation by an international team under the supervision of W. Fairweather.
The The PSI gave a book prize for the best paper. Professor Isao Yoshimura (Science University Tokyo, Japan) was selected as the winner for his excellent paper "Performance comparison of maximum contrast methods to detect dose dependency," published in this issue of the DIA journal.
